Immunotherapy boosts standard treatment for aggressive cervical cancer
NCT ID NCT03738228
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 26 times
Summary
This early-phase trial tested whether adding the immunotherapy drug atezolizumab to standard chemoradiation could help control advanced cervical cancer that has spread to lymph nodes. Forty participants received the drug before and during treatment to see if it activated their immune system against the tumor. The goal was to improve disease control, not to cure the cancer, as ongoing management is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Augusta University Medical Center
Augusta, Georgia, 30912, United States
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390, United States
-
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, 52242, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
-
Women and Infants Hospital
Providence, Rhode Island, 02905, United States
Conditions
Explore the condition pages connected to this study.